The application of AI in the pharmaceutical industry is shifting focus from drug discovery to enhancing commercial operations, revealing significant revenue opportunities.
Recent discussions with pharmaceutical executives indicate that while AI holds promise for drug discovery, its immediate financial impact is more likely to stem from optimizing the commercialization of existing drugs. The industry incurs substantial costs in sales, marketing, and other commercial activities, which are ripe for AI-driven efficiencies. Scotiabank estimates that AI could boost revenue by approximately 3% by 2028 across major biopharma companies, translating to an impressive $770 billion in incremental revenue and nearly $50 billion in cost savings over the next decade.
AI technologies are already improving sales force effectiveness by helping representatives identify the most impactful physicians and tailor their messaging. Tools designed for next-best-action strategies could yield a notable increase in sales for key products. Additionally, AI is streamlining content creation in pharmaceutical marketing, significantly reducing development times and enhancing compliance, which has traditionally slowed the process.
While drug discovery remains a long-term goal, the current focus on commercial applications presents a more immediate avenue for value creation. AI's ability to enhance operational efficiency and reduce costs in marketing and sales may prove more beneficial to established companies than the more speculative potential of drug discovery. As the industry evolves, it’s clear that the true winners in the near term will be those leveraging AI to refine existing commercial frameworks rather than reinvent them.